Current operating income before R&D slightly improving throughout first half of 2023 in percentage of revenue

In France and around the world, the medicalization of cats continues to progress, helping to increase their life expectancy. Two major pathologies affect these aging cats: chronic kidney disease and osteoarthritis. Specially adapted nutrition can help. That's why we're launching VETERINARY HPM^® Kidney & Joint in Europe in September. This new nutrition program enables the combined and gradual management of chronic kidney disease and osteoarthritis, thus improving the animal's quality of life. 

Following the decision of the board of directors on June 19, 2023 and its approval by the shareholder’s meeting, we are going to buy back 100,000 of our own shares (less than 1.25% of the capital). Main objective: to decrease the company's share capital by canceling treasury shares purchased.